For the FIGO clinical stages, the strongly positive rate of NQO1 protein was 80.9% (55/68) in the late-stage (IIB–IIIC) ovarian carcinomas, but only 40.2% (37/92) in early-stage (I–IIA) cases (P = 0.000). This evidence concerns the gene NQO1 and ovarian carcinoma.